subject: 2008 China Pharmaceutical Industry Market Forecasting [print this page] 2007, China Medicine API Market in the winding road, will have gone through an unusual year. In the passing of one year, environmental protection and energy saving solution in the row to establish harmony with the environment of our party and the government's major policies formulated under the guidance of our medical
API Industry in the kind of conditions, because many species produce serious pollution and damage to the environment by the relevant law enforcement departments severe punishment, many Pharmaceutical manufacturers, the time in 2007, the long period of limited production, cut-off state, even to the North China Pharmaceutical companies do not like, "survived." With the increasing pace of the year 2008 approaching, in April 2007 by the State Environmental Protection Administration issued the "emission standards for the pharmaceutical industry", it will be January 1, 2008 officially enforced. It is not difficult to see, in 2008, China Pharmaceutical market conditions, is still around, "the pharmaceutical industry emission standards" changes in the main line changes. Therefore, we can thus on China's Pharmaceutical Industry in 2008 market conditions, accurate forecasts for all to share.
1. China Pharmaceutical manufacturing industry, in turn face new integration and shuffle again
Recent years, the rapid development of China's Pharmaceutical production, from production to production capacity and yield varieties, both from being in the world, became the decisive World Pharmaceutical major force in the market, according to statistics, China's medicine chemical raw total of 1,016 manufacturing enterprises, of which 24 large enterprises, 149 medium-sized and small enterprises 843. Also, China Pharmaceutical manufacturing industry, has been sporadic over the past type orientation of the development to large-scale transformation of enterprises in 1016, 24 large enterprises, 149 medium and 843 small businesses in the industrial output value accounted for 35.14% , 33.13%, 31.73%, in the international market is highly competitive. However, as 2008 approaches, the State Environmental Protection Administration issued the "emission standards for the pharmaceutical industry" on January 1, 2008 began the formal implementation of all the businesses are facing new problems that must be reached " emission standards for the pharmaceutical industry "can be allowed normal production.
Some extent, the rapid development of China's Pharmaceutical Industry, is based on high pollution and high emissions, environmental costs of environmental damage or substantial overdraft acquired, without effective governance, will will have serious consequences, and harming our children and grandchildren. However, the situation of China's Pharmaceutical Industry is very difficult. China Pharmaceutical GMP industrial enterprises have undergone a comprehensive transformation and certification, cost a lot of manpower, material and financial resources, some enterprises due to the transformation and GMP certification, nearly exhausted its "vitality", just over so short a short few years, some industrial enterprises Pharmaceutical GMP certification by the feelings of joy, but got GMP certificate from since, due to financial difficulties of the embarrassment, not to produce a profit, once again facing a new problem, but also a lot of money, a comprehensive reform, to achieve "emission standards for the pharmaceutical industry" can be produced. From this, the State Environmental Protection Administration issued the "emission standards for the pharmaceutical industry" on January 1, 2008 deadline has been formally introduced to, pharmaceutical raw materials producers, inevitably faced with yet another new integration and shuffle, and some companies will be ranked in the wash was shuffling "wash" and is "integrated out." This was the Pharmaceutical industry is facing another harsh reality can not be avoided.
2. Pharmaceutical market situation will remain in short supply
Order to achieve the State Environmental Protection Administration issued the "emission standards for the pharmaceutical industry", to maintain the survival and development, subsequently, the company immediately embarked on reform, will be a lot of time and space occupied by manufacturer resources, capital and production sites from the two levels of view, would seriously affect the normal production of pharmaceutical raw materials. In 2007, the country's pharmaceutical raw materials for the production of polluting enterprises and varieties introduced mandatory measures to limit production shutdown, making some varieties of production and market supply-demand relationship to a "calf pull carts" situation, APIs for basic is to maintain the overall market in tight supply environment conditions. 2008, APIs will add highlights the contradictions in short supply. Also, some companies (mainly small businesses and enterprises with poor economic forces) who were unable to re-invest in the transformation of pollutants, had to stop production, so the Pharmaceutical Market in 2008, there will be some small species or small business products sold off or out of stock of the situation.
